Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study
Although ileal disease is often more treatment resistant, IFX SC maintenance therapy was effective vs PBO regardless of disease location, demonstrating consistent efficacy across segments including the terminal ileum.
Authors
- Stephen B. Hanauer (ORCID: https://orcid.org/0000-0002-3268-932X)
- Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
- Hyunsoo Park (ORCID: https://orcid.org/0000-0001-6924-1919)
- Bincy Abraham (ORCID: https://orcid.org/0000-0003-0308-1224)
- Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Young Nam Lee (ORCID: https://orcid.org/0000-0003-2776-4708)
- Stefan Schreiber
- Dong‐Hyeon Kim (ORCID: https://orcid.org/0000-0003-0585-2432)
- Marla C. Dubinsky
- Jean–Frédéric Colombel
- Miguel Regueiro
Institutions
- Northwestern University (US)
- Vita-Salute San Raffaele University (IT)
- Cleveland Clinic Lerner College of Medicine (US)
- Methodist Hospital (US)
- University Hospital Schleswig-Holstein (DE)
- Amsterdam University Medical Centers (NL)
- Celltrion (South Korea) (KR)
- Case Western Reserve University (US)
- University of Lübeck (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Gastroenterology and Hepatology
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1016/j.cgh.2025.11.017
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00